| Literature DB >> 24903324 |
Trynke Hoekstra1, Celestina Barbosa-Leiker, Bruce R Wright, Jos W R Twisk.
Abstract
This study examined the heterogeneity in BMI development by identifying distinct developmental trajectories. These trajectories were further investigated by relating them to markers of low-grade inflammation later in life. Data from approximately 400 healthy volunteers participating in the Spokane Heart Study were collected in 2-year intervals, and four waves of data were available for the current analyses. Body weight was measured by BMI and low-grade inflammation by high-sensitivity C-reactive protein (CRP) and fibrinogen. Up to date statistical techniques, i.e., latent class growth models, were used to analyse heterogeneity in body weight, and linear regressions were run to analyse possible associations between trajectories of body weight and CRP/fibrinogen levels. Six trajectories were identified (three stable, two increasing, and one decreasing) which differed significantly on CRP/fibrinogen levels, highlighting the importance of weight trajectories. The differences were only partly explained by variations in lifestyle habits.Entities:
Mesh:
Substances:
Year: 2014 PMID: 24903324 PMCID: PMC5644842 DOI: 10.1159/000362570
Source DB: PubMed Journal: Obes Facts ISSN: 1662-4025 Impact factor: 3.942
Fig. 1Six developmental trajectories of BMI.
Model fit indices
| Number of classes | Bayesian information criterion | Bootstrapped likelihood ratio test | Average posterior probability (min-max) | Number of subjects per class |
|---|---|---|---|---|
| 1 | 7,604.838 | not available | 1.00 | 407 |
| 2 | 7,561.913 | <0.001 | 0.916 (0.843–0.988) | 385/22 |
| 3 | 7,532.887 | <0.001 | 0.933 (0.873–0.986) | 8/377/22 |
| 4 | 7,524.385 | <0.001 | 0.922 (0.824–1.00) | 15/2/27/363 |
| 5 | 7,521.011 | <0.001 | 0.897 (0.821–1.00) | 2/13/16/364/12 |
| 6 | 7,527.809 | 0.08 | 0.869 (0.790–1.00) | 2/15/268/8/18/96 |
Characteristics of the distinct developmental patterns of BMI identified in the Spokane Heart Study
| Normative | Increasing to obese | Stable obese | Increasing to severely obese | Stable severely obese | |
|---|---|---|---|---|---|
| Sample size | 268 | 18 | 96 | 8 | 15 |
| Age at baseline | 48.63 (9.82) | 44.11 (8.55) | 48.30 (8.00) | 51.38 (3.85) | 49.67 (5.43) |
| BMI, kg/m2 | |||||
| At visit 1 | 24.55 (24.23–24.84) | 23.94 (22.71–25.18) | 30.29 (29.91–30.67) | 35.00 (32.77–37.23) | 39.00 (36.89–41.11) |
| At visit 2 | 24.90 (24.56–25.25) | 27.56 (26.12–29.00) | 31.00 (30.45–31.55) | 38.00 (35.39–40.61) | 39.07 (37.11–41.46) |
| At visit 3 | 25.24 (24.93–25.54) | 30.50 (29.14–31.86) | 32.04 (31.63–32.45) | 40.62 (37.95–43.30) | 39.36 (37.47–41.25) |
| At visit 4 | 25.54 (25.22–25.84) | 31.00 (29.19–32.81) | 31.87 (31.47–32.28) | 41.88 (39.03–44.72) | 37.87 (34.33–41.39) |
| CRP, mg/dl | |||||
| At visit 1 | 1.65 (1.71) | 1.85 (2.05) | 2.46 (1.95) | 4.43 (2.30) | 4.30 (2.53) |
| At visit 4 | 1.92 (2.07) | 3.75 (2.45) | 3.10 (2.33) | 4.41 (3.17) | 3.95 (2.74) |
| Difference in CRP (visit 4-visit 1) | 0.26 (2.09) | 1.90 (2.14) | 0.57 (2.34) | −0.029 (4.15) | −0.41 (2.38) |
| Fibrinogen, mg/dl | |||||
| At visit 1 | 316.10 (239.33) | 317.81 (100.73) | 310.52 (120.11) | 420.34 (151.01) | 397.68 (91.27) |
| At visit 4 | 346.10 (124.10) | 390.56 (94.09) | 360.39 (157.39) | 490.10 (201.60) | 433.99 (105.61) |
| Difference in fibrinogen (visit 4-visit 1) | 30.27 (249.73) | 72.75 (116.62) | 47.65 (127.85) | 69.76 (161.75) | 36.31 (98.43) |
| % Female | 50.7 | 61.1 | 40.6 | 37.5 | 86.7 |
| % Current smokers at visit 1 | 8.6 | 11.1 | 9.4 | 0.0 | 6.7 |
| % Regular engagement in sports at visit 1 | 38.60 | 27.80 | 22.80 | 37.5 | 13.30 |
| % Restricted diet at visit 1 | 51.5 | 55.6 | 40.6 | 75.0 | 53.3 |
| % Medication use at visit 1 | 12.3 | 0.00 | 13.5 | 62.5 | 33.3 |
Continuous variables are presented as means (SD).
Categorical variables are presented as %.
Regular engagement implies approximately 5 h/week.
Restricted diets included low fat, low salt, low cholesterol or vegetarian.
Relevant medication include medication for cholesterol, blood pressure and/or diabetes.
95% confidence intervals are presented for the BMI values at visit 1–4.
Unstandardised regression coefficients (b), 95% confidence intervals and p values for the associations between BMI-trajectory membership and CRP
| Model 1 | Model 2 | |||||
|---|---|---|---|---|---|---|
| b | 95% confidence interval | p value | b | 95% confidence interval | p value | |
| Increasing to obese | 2.22 | 1.38, 3.58 | 0.001 | 2.10 | 1.32, 3.36 | 0.002 |
| Stable obese | 1.84 | 1.45, 2.33 | <0.001 | 1.72 | 1.36, 2.17 | <0.001 |
| Increasing to severely obese | 3.04 | 1.49, 6.20 | 0.002 | 3.24 | 1.61, 6.54 | 0.001 |
| Stable severely obese | 2.35 | 1.39, 3.97 | 0.002 | 2.20 | 1.32, 3.36 | 0.003 |
Model 1 correcting only for age, gender, relevant medication use and oral contraceptive use.
Model 2 correcting further for lifestyle variables (diet, physical activity, smoking behaviour).
‘Normative’ trajectory is set as the reference category.
Regression coefficients represented as ratios because of log-transformed CRP.
Unstandardised regression coefficients (b), 95% confidence intervals and p values for the associations between BMI-trajectory membership and fibrinogen
| Model 1 | Model 2 | |||||
|---|---|---|---|---|---|---|
| b | 95% confidence interval | p value | b | 95% confidence interval | p value | |
| Increasing to obese | 48.19 | −19.91, 116.29 | 0.165 | 43.14 | −25.86, 112.13 | 0.220 |
| Stable obese | 19.83 | −12.91, 52.57 | 0.234 | 19.85 | −13.49, 53.19 | 0.242 |
| Increasing to severely obese | 155.25 | 55.86, 254.63 | 0.002 | 153.42 | 53.48, 253.37 | 0.003 |
| Stable severely obese | 68.40 | −5.30, 142.10 | 0.069 | 69.35 | −5.11, 143.81 | 0.068 |
Model 1 correcting only for age, gender, relevant medication use and oral contraceptive use.
Model 2 correcting further for lifestyle variables (diet, physical activity, smoking behaviour).
‘Normative’ trajectory is set as the reference category.
Unstandardised regression coefficients (b), 95% confidence intervals and p values for the associations between BMI-trajectory and change scores of CRP and fibrinogen
| CRP | Fibrinogen | |||||
|---|---|---|---|---|---|---|
| b | 95% confidence interval | p value | b | 95% confidence interval | p value | |
|
| ||||||
| Increasing to obese | 1.41 | 0.37, 2.46 | 0.008 | 44.64 | −69.40, 158.69 | 0.442 |
| Stable obese | 0.26 | −0.27, 0.80 | 0.336 | 16.83 | −38.70, 71.70 | 0.547 |
| Increasing to severely obese | 0.24 | −1.32, 1.80 | 0.760 | 79.28 | −87.08, 245.64 | 0.349 |
| Stable severely obese | −0.22 | −1.45, 1.01 | 0.727 | 9.98 | −113.38, 133.34 | 0.874 |
|
| ||||||
|
| ||||||
| Increasing to obese | 1.36 | 0.32, 2.41 | 0.011 | 49.02 | −66.57, 164.60 | 0.405 |
| Stable obese | 0.17 | −0.37, 0.72 | 0.532 | 17.04 | −38.84, 72.92 | 0.549 |
| Increasing to severely obese | 0.34 | −1.23, 0.90 | 0.673 | 84.89 | −82.43, 252.22 | 0.319 |
| Stable severely obese | −0.29 | −1.52, 0.95 | 0.650 | 10.78 | −113.87, 135.43 | 0.865 |
aModel 1 correcting only for age, gender, relevant medication use and oral contraceptive use.
bModel 2 correcting further for lifestyle variables (diet, physical activity, smoking behaviour).
‘Normative’ trajectory is set as the reference category.
Unstandardised regression coefficients (b), 95% confidence intervals and p values for the associations between change scores of BMI and CRP and fibrinogen levels at visit 4
| CRP | Fibrinogen | |||||
|---|---|---|---|---|---|---|
| b | 95% confidence interval | p value | b | 95% confidence interval | p value | |
|
| 1.10 | 1.06, 1.15 | <0.001 | 3.73 | −1.69, 9.15 | 0.177 |
|
| ||||||
|
| 1.10 | 1.06, 1.15 | <0.001 | 3.65 | −1.81, 9.12 | 0.189 |
aModel 1 correcting only for age, gender, relevant medication use and oral contraceptive use
bModel 2 correcting further for lifestyle variables (diet, physical activity, smoking behaviour)
Unstandardised regression coefficients (b), 95% confidence intervals and p values for the associations between change scores of BMI and change scores of CRP and fibrinogen levels
| CRP | Fibrinogen | |||||
|---|---|---|---|---|---|---|
| b | 95% confidence interval | p value | b | 95% confidence interval | p value | |
|
| 0.18 | 0.09, 0.27 | <0.001 | 5.01 | −3.92, 13.94 | 0.271 |
|
| ||||||
|
| 0.19 | 0.10, 0.27 | <0.001 | 5.48 | −3.51, 14.47 | 0.232 |
aModel 1 correcting only for age, gender, relevant medication use and oral contraceptive use.
bModel 2 correcting further for lifestyle variables (diet, physical activity, smoking behaviour).